Table 1. Demographics of patients with ptosis related to myasthenia gravis and controls.
| Myasthenia gravis | Control | p value | |
|---|---|---|---|
| Number | 26 | 38 | |
| Age(yrs) | 39.5 ± 23.5 | 35.2 ± 25.1 | 0.510a |
| Female gender | 14 (53.8%) | 18 (47.4%) | 0.611b |
| Anti-AchR Antibody titer | |||
| Positive | 10 (38.5%) | ||
| Negative | 16 (61.5%) | ||
| Jolly test | |||
| Positive | 9 (34.6%) | ||
| Negative | 17 (65.4%) | ||
| Neostigmine test | |||
| Positive | 5 (19.2%) | ||
| Negative | 13 (50.0%) | ||
| Not tested | 8 (30.8%) | ||
| Treatment | |||
| Pyr | 11 (42.3%) | ||
| Pyr/Pred | 8 (30.8%) | ||
| AZP | 1 (3.8%) | ||
| AZP/Pred | 1 (3.8%) | ||
| Pre-test MRD (mm) | 0.3 ± 1.3 (-2.0~1.5) | 0.8 ± 1.2 (-2.5~1.5) | < 0.001a |
| Change in fissure size (mm) | 1.9 ± 1.3 (0~4.0) | 0.2 ± 0.8 (-1.5~3.0) | < 0.001a |
Means ± SD (range), AChR = Acetylcholine receptor, Pyr = Pyridostigmine Bromide, Pred = Prednisolone, AZP = Azathioprine,
aIndependent t-test,
bχ2 test